Charla Secreto

2.2k total citations
40 papers, 1.3k citations indexed

About

Charla Secreto is a scholar working on Genetics, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Charla Secreto has authored 40 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Genetics, 20 papers in Immunology and 13 papers in Pathology and Forensic Medicine. Recurrent topics in Charla Secreto's work include Chronic Lymphocytic Leukemia Research (40 papers), Lymphoma Diagnosis and Treatment (12 papers) and Phagocytosis and Immune Regulation (11 papers). Charla Secreto is often cited by papers focused on Chronic Lymphocytic Leukemia Research (40 papers), Lymphoma Diagnosis and Treatment (12 papers) and Phagocytosis and Immune Regulation (11 papers). Charla Secreto collaborates with scholars based in United States, Germany and Finland. Charla Secreto's co-authors include Neil E. Kay, Asish K. Ghosh, Tait D. Shanafelt, Debabrata Mukhopadhyay, Traci R. Knox, Clive S. Zent, Wei Ding, Diane F. Jelinek, Betsy LaPlant and Justin C. Boysen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Charla Secreto

39 papers receiving 1.3k citations

Peers

Charla Secreto
Nancy D. Bone United States
Akintunde Akinleye United States
Kim R. Bridle Australia
Jun Ho Yi South Korea
Jiajun Liu China
Yuhua Li China
Jiaohong Wang United States
Mang Xiao China
Jingwei Yu China
Nancy D. Bone United States
Charla Secreto
Citations per year, relative to Charla Secreto Charla Secreto (= 1×) peers Nancy D. Bone

Countries citing papers authored by Charla Secreto

Since Specialization
Citations

This map shows the geographic impact of Charla Secreto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charla Secreto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charla Secreto more than expected).

Fields of papers citing papers by Charla Secreto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charla Secreto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charla Secreto. The network helps show where Charla Secreto may publish in the future.

Co-authorship network of co-authors of Charla Secreto

This figure shows the co-authorship network connecting the top 25 collaborators of Charla Secreto. A scholar is included among the top collaborators of Charla Secreto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charla Secreto. Charla Secreto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Iyer, Prajish, Lu Yang, Sutapa Sinha, et al.. (2023). Beyond CLL Progression: Unveiling Th17 and Th2 T Cell Subsets As Predictors of Pembrolizumab Response in Richter's Transformation. Blood. 142(Supplement 1). 1888–1888.
2.
Wang, Zhiquan, Huihuang Yan, Justin C. Boysen, et al.. (2022). B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells. Blood Cancer Journal. 12(7). 99–99. 4 indexed citations
3.
Wang, Yucai, Sutapa Sinha, Linda Wellik, et al.. (2021). Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. Blood Cancer Journal. 11(5). 86–86. 19 indexed citations
4.
Sinha, Sutapa, Justin C. Boysen, Kari G. Chaffee, et al.. (2018). Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy. Oncotarget. 9(98). 37173–37184. 9 indexed citations
5.
Larsen, Jeremy T., Tait D. Shanafelt, José F. Leis, et al.. (2017). Akt inhibitor MK‐2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study. American Journal of Hematology. 92(8). 759–763. 18 indexed citations
6.
Kay, Neil E., Charla Secreto, Sutapa Sinha, et al.. (2016). Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells. Leukemia & lymphoma. 57(10). 2409–2416. 12 indexed citations
7.
Barrio, Santiago, Tait D. Shanafelt, Juhi Ojha, et al.. (2016). Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome. Leukemia. 31(1). 170–176. 39 indexed citations
8.
Sinha, Sutapa, Justin C. Boysen, Charla Secreto, et al.. (2015). Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. Clinical Cancer Research. 21(9). 2115–2126. 59 indexed citations
9.
Sinha, Sutapa, Justin C. Boysen, Charla Secreto, et al.. (2014). Targeted Inhibition of Axl Primes Chronic Lymphocytic Leukemia B-Cells for Apoptosis: Synergistic/Additive Effects in Combination with Bruton Tyrosine Kinase Inhibitors. Blood. 124(21). 1946–1946. 2 indexed citations
10.
Ojha, Juhi, Jackline de Paula Ayres-Silva, Charla Secreto, et al.. (2014). Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. Blood. 125(3). 492–498. 38 indexed citations
11.
Secreto, Charla, Xiaosheng Wu, Esteban Braggio, et al.. (2014). CLL Mesenchymal Stromal Cells Have Decreased Replicative Potential and Senescent Phenotype: Clinical and Biologic Implications. Blood. 124(21). 3282–3282. 2 indexed citations
12.
Ghosh, Asish K., Charla Secreto, Traci R. Knox, et al.. (2009). Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood. 115(9). 1755–1764. 189 indexed citations
13.
Shanafelt, Tait D., John C. Byrd, Betsy LaPlant, et al.. (2009). Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia. British Journal of Haematology. 146(6). 660–664. 10 indexed citations
14.
Ding, Wei, Grzegorz S. Nowakowski, Traci R. Knox, et al.. (2009). Bi‐directional activation between mesenchymal stem cells and CLL B‐cells: implication for CLL disease progression. British Journal of Haematology. 147(4). 471–483. 68 indexed citations
15.
Ghosh, Asish K., Neil E. Kay, Charla Secreto, & Tait D. Shanafelt. (2009). Curcumin Inhibits Prosurvival Pathways in Chronic Lymphocytic Leukemia B Cells and May Overcome Their Stromal Protection in Combination with EGCG. Clinical Cancer Research. 15(4). 1250–1258. 103 indexed citations
16.
Shanafelt, Tait D., Tim G. Call, Clive S. Zent, et al.. (2009). Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 27(23). 3808–3814. 142 indexed citations
17.
Zent, Clive S., Charla Secreto, Betsy LaPlant, et al.. (2008). Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early–intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leukemia Research. 32(12). 1849–1856. 74 indexed citations
18.
Zent, Clive S., Timothy G. Call, Tait D. Shanafelt, et al.. (2008). Early treatment of high‐risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer. 113(8). 2110–2118. 62 indexed citations
19.
Mukherjee, Priyabrata, Resham Bhattacharya, Nancy D. Bone, et al.. (2007). Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis. Journal of Nanobiotechnology. 5(1). 4–4. 165 indexed citations
20.
Zent, Clive S., Nancy D. Bone, Timothy G. Call, et al.. (2006). Alemtuzumab and Rituximab for Therapy of Patents with Early Stage High Risk CLL: Report of a Planned Interim Analysis.. Blood. 108(11). 2829–2829. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nancy D. Bone Breakdown of academic impact, for papers by Akintunde Akinleye Breakdown of academic impact, for papers by Kim R. Bridle Breakdown of academic impact, for papers by Jun Ho Yi Breakdown of academic impact, for papers by Jiajun Liu Breakdown of academic impact, for papers by Yuhua Li Breakdown of academic impact, for papers by Jiaohong Wang Breakdown of academic impact, for papers by Mang Xiao Breakdown of academic impact, for papers by Jingwei Yu
Rankless by CCL
2026